COMPOSITIONS AND METHODS OF TREATMENT FOR LYTIC AND LYSOGENIC VIRUSES
A composition for treating a lysogenic virus, including isolated nucleic acid encoding two or more gene editors chosen from gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof. A composition for treating a lytic virus, including isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition. A composition for treating both lysogenic and lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA, chosen from CRISPR-associated nucleases, Argonaute endonuclease gDNAs, C2c2, RNase P RNA, and combinations thereof. A composition for treating lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA and a viral RNA targeting composition. Methods of treating a lysogenic virus or a lytic virus, by administering the above compositions to an individual having a virus and inactivating the virus.
1 - 60 . (canceled)
61 . A composition for treating a human immunodeficiency virus (HIV) infection, comprising a nucleic acid encoding Cas9 or Cpf1 and a nucleic acid encoding one or more gene editors that target a viral RNA.
62 . The composition of claim 61 , wherein the gene editor that targets viral RNA is C2c2 or ribonuclease P (RNase P).
63 . The composition of claim 61 , wherein the composition removes a replication critical segment of the HIV DNA or RNA.
64 . The composition of claim 61 , wherein the composition excises the genome of the HIV from a host cell.
65 . A method of treating a human immunodeficiency virus (HIV) infection, comprising administering a composition comprising a nucleic acid encoding Cas9 or Cpf1 and a nucleic acid encoding one or more gene editors that target viral RNA.
66 . The method of claim 65 , wherein the gene editor that targets viral RNA is C2c2 or ribonuclease P (RNase P).
67 . The method of claim 65 , wherein the composition removes a replication critical segment of the HIV DNA or RNA.
68 . The method of claim 65 , wherein the composition excises the genome of the HIV from a host cell.